Real world effectiveness of anti-IL-5/5R therapies is independent of co-eligibility for anti-IgE therapy

Eur Respir J. 2021 Jun 10;57(6):2100166. doi: 10.1183/13993003.00166-2021. Print 2021 Jun.

Authors

Andrew P Hearn^{1

2}, Oliver D Hug², Ziana A Somani², Joanne Kavanagh^{1

2}, Grainne d'Ancona¹, Cris Roxas¹, Linda Green¹, Louise Thomson¹, Mariana Fernandes¹, Brian D Kent^{1

3

4}, Jaideep Dhariwal¹, Alexandra M Nanzer¹, David J Jackson^{5

2}

Affiliations

¹ Guy's Severe Asthma Centre, Guy's Hospital, Guy's and St Thomas' NHS Trust, London, UK.
² School of Immunology and Microbial Sciences, King's College London, London, UK.
³ Dept of Respiratory Medicine, St James' Hospital, Dublin, Ireland.
⁴ School of Medicine, Trinity College Dublin, Dublin, Ireland.
⁵ Guy's Severe Asthma Centre, Guy's Hospital, Guy's and St Thomas' NHS Trust, London, UK David.Jackson@gstt.nhs.uk.

PMID: 33632798
DOI: 10.1183/13993003.00166-2021

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Anti-Idiotypic
Humans
Interleukin-5*
Receptors, Interleukin-5

Substances

Antibodies, Anti-Idiotypic
Interleukin-5
Receptors, Interleukin-5
anti-IgE antibodies